- Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs
- The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program
- Tryp’s management team will address investors in a Fiscal Q3 review on July 29 that also serves as an opportunity to talk about upcoming milestones for the company
- Venture capital investment interest in psychedelic therapies has grown explosively from $1 million in 2017 to $329 million during the first four months of this year alone
Bio-pharmaceutical company
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has spent months building up to the launch of several Phase 2a clinical trials for treating select neurological disorders. On July 29, investors will get the opportunity to ask company officers questions about upcoming initiatives in a Q&A that will be part of Tryp’s Fiscal Q3 Investor Day.
“I am excited to showcase the transformative work that Tryp Therapeutics is doing in collaboration with our academic research partners such as the University of Michigan and the University of Florida,” Tryp Chairman and CEO Greg McKee stated in a news release about the event (
https://ibn.fm/W8nTm). “The next six months represent an important stage in development for us as we initiate multiple Phase 2a clinical trials and move closer to providing additional treatment options for the millions of patients suffering from a variety of chronic pain diseases and eating disorders.”
Tryp’s synthetic psilocybin formulation TRP-8802 is its lead drug candidate and is being developed as a potential treatment for fibromyalgia as well as eating disorders such as binge eating and hypothalamic obesity.
Both disorders are targets for Tryp’s Psilocybin-for-Neuropsychiatric Disorders program (“PFN”) that prioritizes maladies with unmet needs based on limitations within the central nervous system
Tryp is also developing TRP-8803 as another psilocybin-based drug candidate with a proprietary formulation and method of delivery to improve the patient experience.
The Investor Day event will feature a presentation by Tryp’s management team on the PFN program and a discussion on the company’s upcoming milestones.
For those who can’t attend the livestream of the event, a replay will be available for 30 days afterward on Tryp’s website.
Venture capital investment in the psychedelics sector since 2017 has risen explosively from $1 million to $329 million during the first four months of 2021 alone (
https://ibn.fm/p21zW). American psychiatrists as a group have overwhelmingly supported efforts to further use into the use of classic hallucinogens in the treatment of psychiatric disorders, which could have a trickle-down effect for neuropsychiatric issues (
https://ibn.fm/DDxec) and efforts by companies like Tryp to attract funding capital.
Because the Food and Drug Administration (“FDA”) remains the focal point for assessing the potential for substance abuse and possible adverse events, the establishment of rigorous clinical trials with population sizes and conditions that mirror real-world variables is imperative to advancing novel treatment candidates that may form solutions to heretofore unmet needs (
https://ibn.fm/0mzFK).
For more information, visit the company’s website at
www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at
https://ibn.fm/TRYPF
